Short answer
Ginkgo Bioworks Holdings, Inc. (DNA) filed its Q1 2026 10-Q quarterly report on May 7, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $19M (down 59.7% year over year) with net income of −$83M.
Q1 2026 key financials · XBRL
- Revenue
- $19M
- −59.7% YoY
- Net income
- −$83M
- +9.2% YoY
- Operating margin
- -366.5%
- EPS (diluted)
- −$1.39
- +17.3% YoY
Source: XBRL data from the Ginkgo Bioworks Holdings, Inc. (DNA) Q1 2026 10-Q on SEC EDGAR. USD.
Ginkgo Bioworks Holdings, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $19.5M, down $18.8M YoY from $38.2M
- Net loss $76.1M vs $83.3M YoY; operating loss $71.4M vs $81.0M
- Research and development largest expense at $49.9M, down $21.0M YoY
- Cash and marketable securities $373.5M; ATM proceeds $18.1M from 1.9M shares
- R&D and G&A expected consistent or declining in 2026; expenditures expected to exceed revenue through next 12 months
Risk Factors
- No risk-factors section provided in the submitted text
- Stock Purchase Agreement dated February 26, 2026, indicates a potential transaction-related change
- No specific regulatory, legal, operational, competitive, market, liquidity, debt, currency, or concentration risks disclosed
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Ginkgo Bioworks Holdings, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.